Cargando…

Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?

Background BRCA1/2 mutations are the leading cause of hereditary epithelial ovarian cancer (EOC). The German Consortium for Hereditary Breast and Ovarian Cancer has defined inclusion criteria, which are retrievable as a checklist and facilitate genetic counselling/testing for affected persons with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ataseven, Beyhan, Tripon, Denise, Rhiem, Kerstin, Harter, Philipp, Schneider, Stephanie, Heitz, Florian, Baert, Thais, Traut, Alexander, Pauly, Nina, Ehmann, Sarah, Plett, Helmut, Schmutzler, Rita K., du Bois, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467803/ https://www.ncbi.nlm.nih.gov/pubmed/32905297 http://dx.doi.org/10.1055/a-1222-0042

Ejemplares similares

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
por: Moubarak, Malak, et al.
Publicado: (2022)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients
por: Imterat, Majdi, et al.
Publicado: (2023)

Dataset on patients with Recurrent Borderline Ovarian Tumors and Table with Review of Literature on Fertility and Oncologic Outcomes of patients with Borderline Ovarian Tumors
por: Plett, Helmut, et al.
Publicado: (2020)

Response to the letter of Fagotti et al. regarding the manuscript: “Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery”
por: Heitz, Florian, et al.
Publicado: (2016)

Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire
por: Herold, Natalie, et al.
Publicado: (2022)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Long-term survival of a BRCA2 mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report
por: Bredow, Kathrin, et al.
Publicado: (2022)

Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer
por: Heitz, Florian, et al.
Publicado: (2023)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring
por: Braicu, Elena Ioana, et al.
Publicado: (2021)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

The BRCA Gene in Epithelial Ovarian Cancer
por: Sánchez-Lorenzo, Luisa, et al.
Publicado: (2022)

Characterization of BRCA Deficiency in Ovarian Cancer
por: Barbero, Giovanna, et al.
Publicado: (2023)

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
por: O’Mahony, Denise G., et al.
Publicado: (2023)

Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer
por: Herold, Natalie, et al.
Publicado: (2023)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
por: Kalachand, Roshni D., et al.
Publicado: (2020)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
por: Samuel, David, et al.
Publicado: (2022)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

BRCA mutations in the manifestation and treatment of ovarian cancer
por: Pan, Zimin, et al.
Publicado: (2017)

Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making
por: Kautz-Freimuth, Sibylle, et al.
Publicado: (2021)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
por: Birkbak, Nicolai Juul, et al.
Publicado: (2013)

BRCA1 and BRCA2 Germline Mutations Screening in Algerian Breast/Ovarian Cancer Families
por: Cherbal, Farid, et al.
Publicado: (2010)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2018)

BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome
por: Ewald, Ingrid Petroni, et al.
Publicado: (2016)

Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
por: Jasiewicz, Andrzej, et al.
Publicado: (2022)

Analysis of 30 Putative BRCA1 Splicing Mutations in Hereditary Breast and Ovarian Cancer Families Identifies Exonic Splice Site Mutations That Escape In Silico Prediction
por: Wappenschmidt, Barbara, et al.
Publicado: (2012)

Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial
por: Kautz-Freimuth, Sibylle, et al.
Publicado: (2023)

Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients
por: Jarhelle, Elisabeth, et al.
Publicado: (2019)

Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations
por: Wappenschmidt, B, et al.
Publicado: (2001)

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
por: Harter, Philipp, et al.
Publicado: (2017)

BRCA and Early Events in the Development of Serous Ovarian Cancer
por: George, Sophia H. L., et al.
Publicado: (2014)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ofhfv9ui39sqop64srv87t6rh3